CoChat

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8 H)-one (PRN1371) for the Treatment of Solid Tumors

Open access
Brameld, Ken A., Owens, Timothy D., Verner, Erik, Venetsanakos, Eleni, Bradshaw, J. Michael, Phan, Vernon T., Tam, Danny, Leung, Kwan, Shu, Jin, LaStant, Jacob, Loughhead, David G., Ton, Tony, Karr, Dane E., Gerritsen, Mary E., Goldstein, David M., Funk, Jens Oliver · 2017 · Journal of Medicinal Chemistry
Cited by 96

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncology indications. An irreversible covalent binding mechanism imparts many desirable pharmacological benefits including high potency, selectivity, and prolonged target inhibition. Herein we report the structure-based design, medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compound 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b00360

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 96

Metadata

Authors
Brameld, K. A., Owens, T. D., Verner, E., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., Loughhead, D. G., Ton, T., Karr, D. E., Gerritsen, M. E., Goldstein, D. M., & Funk, J. O.
Venue
Journal of Medicinal Chemistry
Published
2017-07-25
Volume
60
Issue
15
Pages
6516-6527
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2724796663
Cited by
96
References
7
FWCI
4.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8 H)-one (PRN1371) for the Treatment of Solid Tumors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00360
The paper
Brameld, K. A., Owens, T. D., Verner, E., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., Loughhead, D. G., Ton, T., Karr, D. E., Gerritsen, M. E., Goldstein, D. M., & Funk, J. O. (2017). Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8 H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00360

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.